Competitive Salary: EMBL: Bioinformatics Software Engineer and Data Manager Lo Germany (DE)

Funding Opportunity RFA-DK-18-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).

Funding Opportunity RFA-CA-19-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The purpose of this FOA is to expand organ site-specific Cancer Immunotherapy Research Projects as components of the Immuno-Oncology Translation Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor progression and evaluating new or improved immunotherapeutic strategies (including combinations with standard or other therapies) resulting in durable anti-cancer responses. Studies should be largely pre-clinical involving clinically-relevant models and endpoints.

Funding Opportunity RFA-CA-19-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this specific FOA is to establish Cancer Immunoprevention Research Projects that will function as components of a Cancer Immunotherapy Consortium (CIC), which will also include Cancer Immunotherapy Research Projects. The CIC will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor initiation and progression, and evaluating new or improved immunopreventive and immunotherapeutic strategies (including combinations with standard or other therapies). Studies should be largely pre-clinical involving clinically-relevant models and endpoints, and have the potential for rapid translation into early-phase clinical applications.

Funding Opportunity RFA-CA-19-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The purpose of this FOA is to employ immuno-engineering principles to design more durable, widely accessible, and less toxic immunoprevention and immunotherapy strategies. The Immuno-engineering to Improve Immunotherapy (i3) Centers will be comprised of multi-disciplinary teams focused on designing and evaluating innovative engineered immunotherapy approaches and collaborating with the Immuno-Oncology Translational Network (IOTN) investigators to improve existing immunotherapeutic modalities.

Funding Opportunity RFA-CA-19-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support UG3/UH3 phased award Projects as part of the expanded Immuno-Oncology Translational Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor initiation and progression and evaluating new or improved immunopreventive and immunotherapeutic strategies (including combinations with standard or other therapies). Studies should be largely pre-clinical involving clinically-relevant models and endpoints, and have the potential for rapid translation into early-phase clinical applications. Applicants responding to this FOA must apply for both the UG3 and UH3 phases together in a single application. Exploratory studies aimed at immune target identification and validation will be supported under UG3. Achievement of the UH2 milestones will be necessary for transition to the UH3 Implementation Phase. UH3 phase may be awarded after administrative review of the UH2 milestones. Provided these milestones are achieved, UH3 phase may continue with development and preclinical testing of specific interventions.

Notice NOT-HL-18-661 from the NIH Guide for Grants and Contracts

Notice NOT-AA-18-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-20-003 from the NIH Guide for Grants and Contracts. This FOA invites applications for a Demography and Economics of Aging and AD/ADRD Coordinating Center (CC) whose purpose is to act as a hub, serving the needs of both traditional Centers on the Demography and Economics of Aging (D and E Centers) and Centers on the Demography and Economics of Alzheimer's Disease and Alzheimer's Related Dementias (D and E Centers on AD/ADRD), as well as the needs of NIA program staff. The goals of the overall D and E Center program are to seed new lines of research in a) the demography and economics of aging and b) on demography, economics and health services research relevant to AD/ADRD, and to grow the number of researchers engaged in these fields through a variety of research and infrastructure activities that are built around specific research themes. The purpose of the CC is to work collaboratively with all participating Center sites to: maintain an active multi-center website; disseminate Center research advances, activities and resources to the research community, policymakers and other relevant stakeholders; maintain a centralized database to track and synthesize progress and outcomes of Center and CC activities for the purpose of annual reporting to individual Centers and to NIA Program Staff, and for future program evaluation by NIA; arrange an annual in-person meeting; foster communication and collaborative activities within and across both D and E Center programs and with other NIA research Centers; serve as the point-of-contact for the overall D and E Centers program by NIA staff, other NIA Centers and the broader scientific community.

Funding Opportunity RFA-AG-20-002 from the NIH Guide for Grants and Contracts. This FOA invites Research and Development Center (P30) grant applications in demography, economics and health services research relevant to Alzheimer's Disease and Alzheimer's Related Dementias (AD/ADRD). Areas of focus that are especially encouraged are: a) National and international population trends in cognitive aging and AD/ADRD; b) Demography of dementia care and caregiving; c) Economic burden of AD/ADRD; d) Impact of health care systems and long-term supports and services on outcomes for persons with dementia and their care providers; e) Impact of health care financing policies on outcomes for persons with dementia and their care providers; f) How regulatory and economic incentives affect access, quality and health outcomes in health and long-term care systems for persons with dementia; g) Disparities in quality and access to dementia care; h) Effects of population-level health delivery and care interventions on outcomes of persons with dementia; and i) National and international projections of dementia caseload, incidence and prevalence.

Funding Opportunity RFA-AG-20-001 from the NIH Guide for Grants and Contracts. This FOA invites Research and Development Center (P30) grant applications in the areas of demography and economics of aging, including relevant interdisciplinary areas rooted in population-based social science research. Areas of focus that are especially encouraged are: a) socioeconomic status (SES) disparities at older ages, including geographic disparities; b) the reasons for poor U.S. performance in health and mortality in international comparisons; c) trends and dynamics in old-age disability; d) cohort trends in obesity and its sequelae; e) family demography including the demography of care and caregiving for chronic disease, disability and Alzheimers Disease and Alzheimer's-Related Dementias, AD/ADRD, and; f) long-term supports and services for the disabled elderly population.

Funding Opportunity RFA-NS-19-009 from the NIH Guide for Grants and Contracts. This FOA is intended to encourage exploratory studies to : (1) increase our understanding of how music affects the brain, body, and behavior and (2) use that knowledge to develop evidence-based music interventions to enhance health or treat specific diseases and disorders. Proposed R21 projects can investigate how music is processed by or modifies the brain, or how it affects specific biological functions during childhood development and learning, adulthood, and aging. Projects can also include preliminary interventions that provide a basis for therapeutic interventions. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.

Funding Opportunity RFA-NS-19-008 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to promote research to both understand the mechanisms by which music is uniquely processed in the brain and optimize music medicine to enrich our lives and treat illness. This FOA encourages a broad variety of R01 research projects from basic to applied approaches, across the lifespan, and in both healthy and diseased individuals. It encourages partnerships and collaborations among basic researchers, technological development researchers, music intervention experts, and/or other clinical researchers.

Funding Opportunity RFA-AT-19-001 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to promote innovative research on music and health with an emphasis on developing music interventions aimed at understanding their mechanisms of action and clinical applications with little or no preliminary data. Because of the need for a multidisciplinary approach, collaborations among basic researchers, translational science researchers, music intervention experts, other clinical researchers, music health professionals, and technology development researchers are encouraged. The FOA utilizes a phased R61/R33 funding mechanism to support mechanistic research and to evaluate the clinical relevance of music interventions. The R61 phase will provide funding for up to two years to either investigate the biological mechanisms or behavioral processes underlying music interventions in relevant animal models, healthy human subjects, and/or clinical populations, or can be used to develop innovative technology or approaches to enhance music intervention research. The second R33 phase will provide up to three years of support for further mechanistic investigations, intervention development, or pilot clinical studies. The pilot clinical studies may focus on intervention optimization/refinement, feasibility, adherence, and/or identification of appropriate outcome measures to inform future clinical research. Transition from the R61 to the R33 phase of the award will depend on successful completion of pre-specified milestones established in the R61.

Negotiable: Paramount Recruitment: Data Scientists - Drug Discovery - Post-Doc Level One of the world's most prestigious pharmaceutical companies is expanding their drug discovery research facility and seeking a talented Bioinformatics, Data Scientists, Machine Learning Enthusiasts, Sta Oxfordshire, England

Funding Opportunity RFA-MH-19-235 from the NIH Guide for Grants and Contracts. The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses. The objectives of the FOA will be accomplished by supporting basic and translational neuroscientists who are committed to improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. As such, this FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans (see PAR-16-065; Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3)). In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental h

Notice NOT-TW-18-007 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Technical Innovator - Bioinformatics Cambridge I have a great opportunity available to work with one of the leading organisations within bioinformati Cambridge, England

Notice NOT-TW-18-008 from the NIH Guide for Grants and Contracts

Notice NOT-ES-19-004 from the NIH Guide for Grants and Contracts